The combination of novel targeted molecular agents and radiation in the treatment of pediatric gliomas

Frontiers in Oncology

Volumn 3 MAY, Issue , 2013, Pages

  Dasgupta, Tina ^a   Haas Kogan, Daphne A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis inhibitors; Bevacizumab; BRAFV600E; Lenalidomide; Low grade glioma; Pediatric gliomas; PI3K AKT mTOR

Indexed keywords

4 (4 AMINO 5 (7 METHOXY 1H INDOL 2 YL) IMIDAZO [5, 1 F] [1, 2, 4] TRIAZIN 7 YL) CYCLOHEXANECARBOXYLIC ACID; 4 (4 AMINO 5 (7 METHOXY 1H INDOL 2 YL)IMIDAZO[5,1 F][1,2,4]TRIAZIN 7 YL)CYCLOHEXANECARBOXYLIC ACID; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE; AZD 2014; AZD 8055; B RAF KINASE; CC 5103; CETUXIMAB; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DABRAFENIB; DACARBAZINE; DACTOLISIB; EVEROLIMUS; GAMMA INTERFERON; GNE 317; INITIATION FACTOR 4E BINDING PROTEIN 1; INTERLEUKIN 10; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MLN0128; N [3 (5 CHLORO 1H PYRROLO [2, 3 B] PYRIDINE 3 CARBONYL) 2, 4 DIFLUOROPHENYL] PROPANESULFONAMIDE; PBTC018; PHOSPHATIDYLINOSITOL 3 KINASE; RAPAMYCIN; TACROLIMUS; TEMSIROLIMUS; THALIDOMIDE DERIVATIVE; TORIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEMURAFENIB; WYE 354; XL 765;

ANGIOGENESIS; BONE MARROW SUPPRESSION; CANCER RADIOTHERAPY; CONVULSION; FATIGUE; FEVER; GENE EXPRESSION; GLIOMA; HUMAN; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; OTITIS MEDIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY DISORDER; PILOCYTIC ASTROCYTOMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINUSITIS; STOMATITIS; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; UPPER RESPIRATORY TRACT INFECTION; VENOUS THROMBOEMBOLISM;

EID: 84891063193     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00110     Document Type: Review

References (78)

1. Alexander, B. M., Wang, M., Yung, W. K., Fine, H. A., Donahue, B. A., Tremont, I. W., et al. (2013). A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806). J. Neurooncol. 111, 33-39.
2. Arbab, A. S. (2012). Activation of alternative pathways of angiogenesis and involvement of stem cells following anti-angiogenesis treatment in glioma. Histol. Histopathol. 27, 549-557.
3. Bhagwat, S. V., Gokhale, P. C., Crew, A. P., Cooke, A., Yao, Y., Mantis, C., et al. (2011). Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol. Cancer Ther. 10, 1394-1406.
4. Butowski, N. (2011). Anti-angiogenic therapy in glioma. Clin. Transl. Oncol. 13, 294-300.
5. Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516.
6. Couec, M. L., André, N., Thebaud, E., Minckes, O., Rialland, X., Corradini, N., et al. (2012). Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: toxicity and efficacy trends. Pediatr. Blood Cancer 59, 34-38.
7. Dasgupta, T., Olow, A., Yang, X., Nicolaides, T., and Haas-Kogan, D. A. (2013). Survival advantage with Everolimus (RAD001) combined with a selective BRAFV600E Inhibitor in a Xenograft Model of BRAFV600E-mutated Pediatric Glioma. Oncology 27(Suppl. 1), 1.
8. Dasgupta, T., Yang, X., Hashizume, R., Olow, A., Kolkowitz, I., Weiss, W., et al. (2012). Survival advantage with radiation combined with a selective BRAFV600E inhibitor in an orthotopic, intracranial model of BRAFV600E-mutated high-grade gliomas. Int. J. Radiat. Oncol. Biol. Phys. 83(Suppl. 3), S125.
9. Dhermain, F., Saliou, G., Parker, F., Page, P., Hoang-Xuan, K., Lacroix, C., et al. (2010). Microvascular leakage and contrast enhancement as prognostic factors for recurrence in unfavorable low-grade gliomas. J. Neurooncol. 97, 81-88.
10. Doghman, M., and Lalli, E. (2012). Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma. Mol. Cell. Endocrinol. 364, 101-104.
11. Dougherty, M. J., Santi, M., Brose, M. S., Ma, C., Resnick, A. C., Sievert, A. J., et al. (2010). Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro-oncology 12, 621-630.
12. Dubois, S. G., Shusterman, S., Ingle, A. M., Ahern, C. H., Reid, J. M., Wu, B., et al. (2011). Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study. Clin. Cancer Res. 17, 5113-5122.
13. Ermoian, R. P., Furniss, C. S., Lamborn, K. R., Basila, D., Berger, M. S., Gottschalk, A. R., et al. (2002). Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival. Clin. Cancer Res. 8, 1100-1106.
14. Falchook, G. S., Long, G. V., Kurzrock, R., Kim, K. B., Arkenau, T. H., Brown, M. P., et al. (2012). Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase I dose-escalation trial. Lancet 379, 1893-1901.
15. Fasolo, A., and Sessa, C. (2012). Targeting mTOR pathways in human malignancies. Curr. Pharm. Des. 18, 2766-2777.
16. Fine, H. A., Kim, L., Albert, P. S., Duic, J. P., Ma, H., Zhang, W., et al. (2007). A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. Clin. Cancer Res. 13, 7101-7106.
17. Folkerth, R. D. (2000). Descriptive analysis and quantification of angiogenesis in human brain tumors. J. Neurooncol. 50, 165-172.
18. Gaiser, T., Becker, M. R., Meyer, J., Habel, A., and Siegelin, M. D. (2009). p53-Mediated inhibition of angiogenesis in diffuse low-grade astrocytomas. Neurochem. Int. 54, 458-463.
19. Giglio, P., Dhamne, M., Hess, K. R., Gilbert, M. R., Groves, M. D., Levin, V. A., et al. (2012). Puduvalli VK, phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma. Cancer 118, 3599-3606.
20. Gilbert, M. R., Gonzalez, J., Hunter, K., Hess, K., Giglio, P., Chang, E., et al. (2010). A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. Neuro-oncology 12, 1167-1172.
21. Gilheeney, S. W., and Kieran, M. W. (2012). Differences in molecular genetics between pediatric and adult malignant astrocytomas: age matters. Future Oncol. 8, 549-558.
22. Haas-Kogan, D. A., Phillips, J. J., Molinaro, A., Wahl, M., Mueller, S., Weiss, W. A., et al. (2013). "Imaging parameters and molecular correlates as predictive markers of treatment response to mTOR inhibitor in adults with recurrent low-grade gliomas," in American Association for Cancer Research (AACR), Washington.
23. Hauschild, A., Grob, J. J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., et al. (2012). Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380, 358-365.
24. Hawkins, C., Walker, E., Mohamed, N., Zhang, C., Jacob, K., Shirinian, M., et al. (2011). BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin. Cancer Res. 17, 4790-4798.
25. Hoang, B., Benavides, A., Shi, Y., Yang, Y., Frost, P., Gera, J., et al. (2012). The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)/eukaryotic translation initiation factor 4E (eIF-4E)/RAF pathway and activation is a mechanism of resistance. J. Biol. Chem. 287, 21796-21805.
26. Horbinski, C., Hamilton, R. L., Nikiforov, Y., and Pollack, I. F. (2010). Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas. Acta Neuropathol. 119, 641-649.
27. Horbinski, C., Nikiforova, M. N., Hagenkord, J. M., Hamilton, R. L., and Pollack, I. F. (2012). Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas. Neuro-oncology 14, 777-789.
28. Ida, C. M., Lambert, S. R., Rodriguez, F. J., Voss, J. S., Mc Cann, B. E., Seys, A. R., et al. (2012). BRAF alterations are frequent in cerebellar low-grade astrocytomas with diffuse growth pattern. J. Neuropathol. Exp. Neurol. 71, 631-639.
29. Jang, S., and Atkins, M. B. (2013). Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol. 14, e60-e69.
30. Jensen, R. L. (1998). Growth factor-mediated angiogenesis in the malignant progression of glial tumors: a review. Surg. Neurol. 49, 189-195; discussion 196.
31. Jentoft, M., Giannini, C., Cen, L., Scheithauer, B. W., Hoesley, B., Sarkaria, J. N., et al. (2010). Phenotypic variations in NF1-associated low grade astrocytomas: possible role for increased mTOR activation in a subset. Int. J. Clin. Exp. Pathol. 4, 43-57.
32. Karajannis, M. A. (2011). Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas. Available at: http://clinicaltrials.gov/show/NCT01338857
33. Kaul, A., Chen, Y. H., Emnett, R. J., Dahiya, S., and Gutmann, D. H. (2012). Pediatric glioma-associated KIAA1549:BRAF expression regulates neuroglial cell growth in a cell type-specific and mTOR-dependent manner. Genes Dev. 26, 2561-2566.
34. Kesari, S., Schiff, D., Henson, J. W., Muzikansky, A., Gigas, D. C., Doherty, L., et al. (2008). Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro-oncology 10, 300-308.
35. Kim, C. Y., Kim, S. K., Phi, J. H., Lee, M. M., Kim, I. A., Kim, I. H., et al. (2010). A prospective study of temozolomide plus thalidomide during and after radiation therapy for pediatric diffuse pontine gliomas: preliminary results of the Korean Society for Pediatric Neuro-Oncology study. J. Neurooncol. 100, 193-198.
36. Krueger, D. A., Care, M. M., Holland, K., Agricola, K., Tudor, C., Mangeshkar, P., et al. (2010). Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N. Engl. J. Med. 363, 1801-1811.
37. Kumar, V., and Chhibber, S. (2011). Thalidomide: an old drug with new action. J. Chemother. 23, 326-334.
38. Lang, S.-S., Sievert, A. L., Boucher, K. L., Madsen, P. J., Slaunwhite, E., Brewington, D., et al. (2012). Development of pediatric glioma models for BRAF-targeted therapy. Neurosurgery 71, E575.
39. Laplante, M., and Sabatini, D. M. (2012). mTOR signaling in growth control and disease. Cell 149, 274-293.
40. Leon, S. P., Folkert, R. D., and Black, P. M. (1996). Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 77, 362-372.
41. Lin, A., Rodriguez, F. J., Karajannis, M. A., Williams, S. C., Legault, G., Zagzag, D., et al. (2012). BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549:BRAF fusion variants. J. Neuropathol. Exp. Neurol. 71, 66-72.
42. Long, G. V., Trefzer, U., Davies, M. A., Kefford, R. F., Ascierto, P. A., Chapman, P. B., et al. (2012). Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 13, 1087-1095.
43. Lorgis, V., Maura, G., Coppa, G., Hassani, K., Taillandierm, L., Chauffert, B., et al. (2012). Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohorts. J. Neurooncol. 107, 351-358.
44. Mahadevan, D., Chiorean, E. G., Harris, W. B., Von Hoff, D. D., Stejskal-Barnett, A., Qi, W., et al. (2012). Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. Eur. J. Cancer. 48, 3319-3327.
45. Manning, B. D., and Cantley, L. C. (2007). AKT/PKB signaling: navigating downstream. Cell 129, 1261-1274.
46. Mansfield, J. C., Parkes, M., Hawthorne, A. B., Forbes, A., Probert, C. S., Perowne, R. C., et al. (2007). A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease. Aliment. Pharmacol. Ther. 26, 421-430.
47. McBride, S. M., Perez, D. A., Polley, M. Y., Vandenberg, S. R., Smith, J. S., Zheng, S., et al. (2010). Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival. J. Neurooncol. 97, 33-40.
48. McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Montalto, G., Cervello, M., et al. (2012). Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget 3, 954-987.
49. Moehler, T. (2012). Clinical experience with thalidomide and lenalidomide in multiple myeloma. Curr. Cancer Drug Targets 12, 372-390.
50. Molckovsky, A., and Siu, L. L. (2008). First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting. J. Hematol. Oncol. 1, 20.
51. Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., et al. (2008). Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372, 449-456.
52. Nakamura, M., Shimada, K., Ishida, E., Higuchi, T., Nakase, H., Sakaki, T., et al. (2007). Molecular pathogenesis of pediatric astrocytic tumors. Neuro-oncology 9, 113-123.
53. Nghiemphu, P. L., Omuro, A. M., Cloughesy, T., Mellinghoff, I. K., Norden, A. D., Nguyen, L. T., et al. (2010). A phase I safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with newly diagnosed malignant glioma. J. Clin. Oncol. 28, abstr. 3085.
54. Nicolaides, T. P., Li, H., Solomon, D. A., Hariono, S., Hashizume, R., Barkovich, K., et al. (2011). Targeted therapy for BRAFV600E malignant astrocytoma. Clin. Cancer Res. 17, 7595-7604.
55. Parekh, C., Jubran, R., Erdreich-Epstein, A., Panigrahy, A., Bluml, S., Finlay, J., et al. (2011). Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen. J. Neurooncol. 103, 673-680.
56. Piepmeier, J. M. (1987). Observations on the current treatment of low-grade astrocytic tumors of the cerebral hemispheres. J. Neurosurg. 67, 177-181.
57. Populo, H., Lopes, J. M., and Soares, P. (2012). The mTOR signalling pathway in human cancer. Int. J. Mol. Sci. 13, 1886-1918.
58. Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., et al. (2012). Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100-103.
59. Prasad, G., Sottero, T., Yang, X., Mueller, S., James, C. D., Weiss, W. A., et al. (2011). Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro-oncology 13, 384-392.
60. Puputti, M., Tynninen, O., Pernilä, P., Salmi, M., Jalkanen, S., Paetau, A., et al. (2010). Expression of KIT receptor tyrosine kinase in endothelial cells of juvenile brain tumors. Brain Pathol. 20, 763-770.
61. Riva, M., Imbesi, F., Beghi, E., Galli, C., Citterio, A., Trapani, P., et al. (2007). Temozolomide and thalidomide in the treatment of glioblastoma multiforme. Anticancer Res. 27, 1067-1071.
62. Rodriguez, E. F., Scheithauer, B. W., Giannini, C., Rynearson, A., Cen, L., Hoesley, B., et al. (2011). PI3K/AKT pathway alterations are associated with clinically aggressive and histologically anaplastic subsets of pilocytic astrocytoma. Acta Neuropathol. 121, 407-420.
63. Ruiz, J., Case, D., Enevold, G., Rosdhal, R., Tatter, S. B., Ellis, T. L., et al. (2012). A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas. J. Neurooncol. 106, 611-617.
64. Rush, S., Foreman, N., and Liu, A. (2013). Brainstem ganglioglioma successfully treated with vemurafenib. J. Clin. Oncol. 31, e159-e160.
65. Salphati, L., Heffron, T. P., Alicke, B., Nishimura, M., Barck, K., Carano, R. A., et al. (2012). Targeting the PI3K pathway in the brain-efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier. Clin. Cancer Res. 18, 6239-6248.
66. Samad, N., and Younes, A. (2010). Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma. Onco Targets Ther. 3, 167-178.
67. Schiffman, J. D., Hodgson, J. G., VandenBerg, S. R., Flaherty, P., Polley, M. Y., Yu, M., et al. (2010). Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res. 70, 512-519.
68. Schindler, G., Capper, D., Meyer, J., Janzarik, W., Omran, H., Herold-Mende, C., et al. (2011). Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 121, 397-405.
69. Segler, A., and Tsimberidou, A. M. (2012). Lenalidomide in solid tumors. Cancer Chemother. Pharmacol. 69, 1393-1406.
70. Shortt, J., Hsu, A. K., and Johnstone, R. W. (2013). Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy. Oncogene. doi:10.1038/onc.2012.599
71. Sie, M., de Bont, E. S., Scherpen, F. J., Hoving, E. W., and den Dunnen, W. F. (2010). Tumour vasculature and angiogenic profile of paediatric pilocytic astrocytoma; is it much different from glioblastoma? Neuropathol. Appl. Neurobiol. 36, 636-647.
72. Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J., et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996.
73. Sweet, J. A., Feinberg, M. L., and Sherman, J. H. (2012). The role of avastin in the management of recurrent glioblastoma. Neurosurg. Clin. N. Am. 23, 331-341, x.
74. Tian, Y., Rich, B. E., Vena, N., Craig, J. M., Macconaill, L. E., Rajaram, V., et al. (2011). Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas. J. Mol. Diagn. 13, 669-677.
75. Turner, C. D., Chi, S., Marcus, K. J., MacDonald, T., Packer, R. J., Poussaint, T. Y., et al. (2007). Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme. J. Neurooncol. 82, 95-101.
76. Wang, H. J., Cao, J. P., Yu, J. K., and Gao, D. S. (2007). Role of PI3-K/Akt pathway and its effect on glial cell line-derived neurotrophic factor in midbrain dopamine cells. Acta Pharmacol. Sin. 28, 166-172.
77. Warren, K. E., Goldman, S., Pollack, I. F., Fangusaro, J., Schaiquevich, P., Stewart, C. F., et al. (2011). Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018. J. Clin. Oncol. 29, 324-329.
78. Wick, W., Wick, A., Weiler, M., and Weller, M. (2011). Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence. Curr. Neurol. Neurosci. Rep. 11, 305-312.